NASDAQ$INGN

Inogen Inc · Q4 2019 earnings

Q4 2019 earnings · · Investor relations

Briefing

Inogen's revenue declined due to decrease in direct-to-consumer, domestic business-to-business, and international business-to-business sales.

Inogen reported a decline in total revenue for the fourth quarter of 2019, with decreases in direct-to-consumer, domestic business-to-business, and international business-to-business sales. The company experienced an operating loss and a net loss for the quarter, with a decrease in total gross margin. However, the company is maintaining its full year 2020 total revenue guidance.

  • Total revenue decreased by 8.8% to $78.9 million compared to the same period in 2018.
  • Direct-to-consumer sales declined by 2.8% to $35.8 million.
  • The company reported an operating loss of $5.3 million, compared to an operating income of $4.8 million in the same period in 2018.
  • Net loss was $1.4 million, compared to net income of $10.0 million in the fourth quarter of 2018.

Headline financials

Total Revenue

$78.9M

Previous: $86.5M-8.8%
EPS (adj)

$0.06

Previous: $0.44-86.4%
Capital Expenditures

$868K

Previous: $803K+8.1%
Free Cash Flow

$8.52M

Previous: $11.5M-26.1%
Net Income

-$1.38M

Previous: $10M-113.7%
Operating Income

-$5.32M

Previous: $4.78M-211.4%
Gross Profit

$33.9M

Previous: $43.6M-22.1%
Cash & Equivalents

$198M

Previous: $197M+0.7%
Total Assets

$447M

Previous: $376M+19.0%
Stock-Based Comp

$2.2M

Previous: $3.01M-26.9%

Revenue & EPS history

Inogen · Revenue · Quarterly

$78.9M

Q4 2019-8.8%vs Q4 2018
Beat estimate in 12 of 16 quarters(75%)
ActualEstimate

Forward guidance

Inogen is maintaining its full year 2020 total revenue guidance range provided on January 13, 2020 of $385 to $400 million, representing growth of 6.4% to 10.5% versus 2019 full year results. The Company is reducing its full year 2020 GAAP net income guidance range to $14 to $18 million from the range of $25 to $27 million provided on November 5, 2019, compared to 2019 GAAP net income of $21.0 million. Inogen is lowering its guidance range for full year 2020 Adjusted EBITDA to $44 to $50 million from the range of $56 to $58 million provided on November 5, 2019, compared to 2019 Adjusted EBITDA of $43.3 million.

Tailwinds

  • Direct-to-consumer sales expected to be the fastest-growing channel.
  • Domestic and international business-to-business sales expected to have solid growth.
  • Rental revenue expected to grow modestly due to increase in patients on service.
  • Rental revenue expected to grow modestly due to low, single-digit percent rate increase in 2020 for Medicare beneficiaries.
  • Net positive cash flow expected for 2020 with no additional equity capital required.

Headwinds

  • Minimal contribution of the Inogen Tidal Assist Ventilator for revenue in both the domestic business-to-business and direct-to-consumer channels in 2020.
  • Net income guidance decreased primarily due to lower revenue estimates than previously expected.
  • Net income guidance decreased due to various manufacturing inefficiencies, particularly in the first quarter of 2020.
  • Company expects to have a net loss in the first quarter of 2020.
  • Adjusted EBITDA guidance lowered due to lower revenue estimates.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2019

Historical avgQ4 2019

-0.7%

Avg return

Earnings day

-2.0%

Avg return

5 days after

-2.0%

Avg return

30 days after

49%

26 / 53 earnings

Positive

+35.5%

Q2 2024

Best reaction

-32.2%

Q4 2023

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-2.4%-5.3%-11.0%
Q4 2025+4.3%+5.8%+6.0%
Q3 2025-0.6%+0.9%-1.3%
Q1 2025-11.5%-14.4%-8.1%
Q4 2024-14.8%-14.6%-28.6%
Q3 2024+15.9%+9.1%-0.7%
Q2 2024+35.5%+50.6%+43.0%
Q1 2024+14.6%+17.7%+17.7%
Q4 2023-32.2%-24.3%-13.0%
Q3 2023-1.3%-8.1%+10.0%
Q2 2023-14.6%-18.7%-20.8%
Q1 2023-6.1%-19.3%-21.9%
Q4 2022-31.4%-32.4%-46.4%
Q3 2022-12.5%-10.0%-0.8%
Q2 2022-6.9%-7.3%-6.3%
Q1 2022-2.2%-7.8%+2.0%
Q4 2021+12.6%+25.3%+13.5%
Q3 2021-6.0%-7.3%-21.6%
Q2 2021-22.8%-16.8%-22.1%
Q1 2021-3.5%-2.4%-12.8%
Q4 2020+4.6%+5.4%-4.2%
Q3 2020-7.1%+9.8%+33.0%
Q2 2020+16.4%+17.0%-6.5%
Q1 2020-21.4%-20.1%-24.2%
Q4 2019+10.2%+5.4%+26.4%
Q3 2019+17.3%+19.7%+24.4%
Q2 2019-15.4%-18.5%-20.9%
Q1 2019-28.8%-22.2%-31.8%
Q4 2018-26.4%-25.9%-35.1%
Q3 2018-18.8%-22.6%-24.8%
Q2 2018+7.7%+6.3%+21.3%
Q1 2018+21.0%+18.7%+26.7%
Q4 2017-9.3%-8.4%-7.8%
Q3 2017+16.1%+12.9%+15.0%
Q2 2017-5.6%-3.9%+0.3%
Q1 2017+0.2%-2.6%+11.9%
Q4 2016+6.8%+6.0%+11.4%
Q3 2016+13.0%+15.8%+22.3%
Q2 2016+0.9%+9.3%+8.9%
Q1 2016-6.6%
Q4 2015+20.6%
Q3 2015-1.8%
Q2 2015+13.0%
Q1 2015+4.9%
Q4 2014+1.8%
Q4 2012+1.8%
Q3 2013-1.7%
Q3 2014+6.0%
Q2 2014+3.6%
Q2 2013+3.6%
Q1 2013+12.7%
Q1 2014+12.7%
Q4 2013-1.0%
Q3 2012

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro